Pfizer has announced an increase in production: it will distribute 10% more vaccines in the United States

Pfizer Pharmaceutical has increased production of its COVID-19 vaccine and will be able to deliver 10% more doses to the United States by the end of MayGeneral manager Albert Bourla said in a tweet on Tuesday.

The company will be able to deliver 10% more doses to the United States by the end of May than previously agreed (a total of 220 million), and provide the full 300 million agreed by the end of July, two weeks in advance, Bourla said, adding: “in the fight against COVID-19, we stand together.”

The news comes at the right time, following Johnson & Johnson’s (J&J) recommendation to discontinue use of the vaccine.

The hiatus occurs because U.S. health officials have detected six adverse cases in six vaccinated women between the ages of 18 and 48, one of whom died and the other severe, after developing a rare type of cerebral thrombosis.

Until now, United States granted emergency use authorization for anti-covid preparations from Pfizer and Moderna, which require two doses, and that of J&J, which is a single dose, while AstraZeneca has not yet requested authorization.

J & J’s is not the only vaccine whose administration has been suspended worldwide, since Several countries have also stopped the use of AstraZeneca serum after detecting cases of thrombi.

On Sunday, researchers who conducted a study in Israel reported that the South African variant of the coronavirus has a greater ability to “pierce” the defenses of the Pfizer / BioNTech vaccine than other forms of the virus.

This study by Tel Aviv University and Clalit, the country’s leading health fund, compared 400 unvaccinated people who contracted covid-19 along with 400 other partially or fully vaccinated people who also contracted it.

Israel is immunizing its population with the vaccine of the American-German duo.

According to this study published on Saturday but Not yet evaluated by its peers, less than 1% of contaminations in Israel are due to the South African variant.

But between 150 people having received the two necessary doses of the vaccine, “the prevalence rate (of the South African variant) was eight times higher than in unvaccinated people”, the study said.

“This means that the vaccine Pfizer / BioNtech, while highly protective, likely does not offer the same level of protection against the South African variant of the coronavirus“That compared to other variants of the virus.

With information from Reuters, AFP, EFE

KEEP READING: